A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine
Yuen H Kwok,1 James E Swift,1 Parisa Gazerani,2 Paul Rolan1 1Discipline of Pharmacology, University of Adelaide, Level 5 Medical School North, South Australia, Australia; 2Department of Health Science & Technology, Aalborg University, Aalborg, Denmark Background: Chronic migraine (CM) is pr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-10-01
|
| Series: | Journal of Pain Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-double-blind-randomized-placebo-controlled-pilot-trial-to-determine--peer-reviewed-article-JPR |
| _version_ | 1818008411416035328 |
|---|---|
| author | Kwok YH Swift JE Gazerani P Rolan P |
| author_facet | Kwok YH Swift JE Gazerani P Rolan P |
| author_sort | Kwok YH |
| collection | DOAJ |
| description | Yuen H Kwok,1 James E Swift,1 Parisa Gazerani,2 Paul Rolan1 1Discipline of Pharmacology, University of Adelaide, Level 5 Medical School North, South Australia, Australia; 2Department of Health Science & Technology, Aalborg University, Aalborg, Denmark Background: Chronic migraine (CM) is problematic, and there are few effective treatments. Recently, it has been hypothesized that glial activation may be a contributor to migraine; therefore, this study investigated whether the potential glial inhibitor, ibudilast, could attenuate CM. Methods: The study was of double-blind, randomized, placebo-controlled, two-period crossover design. Participants were randomized to receive either ibudilast (40 mg twice daily) or placebo treatment for 8 weeks. Subsequently, the participants underwent a 4-week washout period followed by a second 8-week treatment block with the alternative treatment. CM participants completed a headache diary 4 weeks before randomization throughout both treatment periods and 4 weeks after treatment. Questionnaires assessing quality of life and cutaneous allodynia were collected on eight occasions throughout the study. Results: A total of 33 participants were randomized, and 14 participants completed the study. Ibudilast was generally well tolerated with mild, transient adverse events, principally nausea. Eight weeks of ibudilast treatment did not reduce the frequency of moderate to severe headache or of secondary outcome measures such as headache index, intake of symptomatic medications, quality of life or change in cutaneous allodynia. Conclusion: Using the current regimen, ibudilast does not improve migraine with CM participants. Keywords: chronic migraine, glia, ibudilast, headache, immune system |
| first_indexed | 2024-04-14T05:28:52Z |
| format | Article |
| id | doaj.art-0fff970bf87e48ab96a502d19245d742 |
| institution | Directory Open Access Journal |
| issn | 1178-7090 |
| language | English |
| last_indexed | 2024-04-14T05:28:52Z |
| publishDate | 2016-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Pain Research |
| spelling | doaj.art-0fff970bf87e48ab96a502d19245d7422022-12-22T02:09:53ZengDove Medical PressJournal of Pain Research1178-70902016-10-01Volume 989990729782A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraineKwok YHSwift JEGazerani PRolan PYuen H Kwok,1 James E Swift,1 Parisa Gazerani,2 Paul Rolan1 1Discipline of Pharmacology, University of Adelaide, Level 5 Medical School North, South Australia, Australia; 2Department of Health Science & Technology, Aalborg University, Aalborg, Denmark Background: Chronic migraine (CM) is problematic, and there are few effective treatments. Recently, it has been hypothesized that glial activation may be a contributor to migraine; therefore, this study investigated whether the potential glial inhibitor, ibudilast, could attenuate CM. Methods: The study was of double-blind, randomized, placebo-controlled, two-period crossover design. Participants were randomized to receive either ibudilast (40 mg twice daily) or placebo treatment for 8 weeks. Subsequently, the participants underwent a 4-week washout period followed by a second 8-week treatment block with the alternative treatment. CM participants completed a headache diary 4 weeks before randomization throughout both treatment periods and 4 weeks after treatment. Questionnaires assessing quality of life and cutaneous allodynia were collected on eight occasions throughout the study. Results: A total of 33 participants were randomized, and 14 participants completed the study. Ibudilast was generally well tolerated with mild, transient adverse events, principally nausea. Eight weeks of ibudilast treatment did not reduce the frequency of moderate to severe headache or of secondary outcome measures such as headache index, intake of symptomatic medications, quality of life or change in cutaneous allodynia. Conclusion: Using the current regimen, ibudilast does not improve migraine with CM participants. Keywords: chronic migraine, glia, ibudilast, headache, immune systemhttps://www.dovepress.com/a-double-blind-randomized-placebo-controlled-pilot-trial-to-determine--peer-reviewed-article-JPRChronic migrainegliaibudilastheadache |
| spellingShingle | Kwok YH Swift JE Gazerani P Rolan P A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine Journal of Pain Research Chronic migraine glia ibudilast headache |
| title | A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine |
| title_full | A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine |
| title_fullStr | A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine |
| title_full_unstemmed | A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine |
| title_short | A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine |
| title_sort | double blind randomized placebo controlled pilot trial to determine the efficacy and safety of ibudilast a potential glial attenuator in chronic migraine |
| topic | Chronic migraine glia ibudilast headache |
| url | https://www.dovepress.com/a-double-blind-randomized-placebo-controlled-pilot-trial-to-determine--peer-reviewed-article-JPR |
| work_keys_str_mv | AT kwokyh adoubleblindrandomizedplacebocontrolledpilottrialtodeterminetheefficacyandsafetyofibudilastapotentialglialattenuatorinchronicmigraine AT swiftje adoubleblindrandomizedplacebocontrolledpilottrialtodeterminetheefficacyandsafetyofibudilastapotentialglialattenuatorinchronicmigraine AT gazeranip adoubleblindrandomizedplacebocontrolledpilottrialtodeterminetheefficacyandsafetyofibudilastapotentialglialattenuatorinchronicmigraine AT rolanp adoubleblindrandomizedplacebocontrolledpilottrialtodeterminetheefficacyandsafetyofibudilastapotentialglialattenuatorinchronicmigraine AT kwokyh doubleblindrandomizedplacebocontrolledpilottrialtodeterminetheefficacyandsafetyofibudilastapotentialglialattenuatorinchronicmigraine AT swiftje doubleblindrandomizedplacebocontrolledpilottrialtodeterminetheefficacyandsafetyofibudilastapotentialglialattenuatorinchronicmigraine AT gazeranip doubleblindrandomizedplacebocontrolledpilottrialtodeterminetheefficacyandsafetyofibudilastapotentialglialattenuatorinchronicmigraine AT rolanp doubleblindrandomizedplacebocontrolledpilottrialtodeterminetheefficacyandsafetyofibudilastapotentialglialattenuatorinchronicmigraine |